Abstract
Malignant glioma remains a disease with poor prognosis despite recent advances in the multidisciplinary care of this disease. Herein we review the evolution of and recent advances in radiation therapy for malignant glioma that have allowed for more targeted therapy, potentially improving efficacy while decreasing normal tissue toxicity. Current and emerging techniques are presented, including stereotactic radiotherapy and radiosurgery, brachytherapy, radioimmunotherapy, and charged particle therapy, as well as the combination of these modalities with novel targeted biochemotherapies.
Keywords: Brachytherapy, charged particle therapy, glioma, radiotherapy, radiosurgery, radioimmunotherapy, biochemotherapies, Glioblastoma multiforme (GBM), radiosensitizers, CT scans
Current Drug Discovery Technologies
Title:Targeted Radiotherapy for Malignant Gliomas
Volume: 9 Issue: 4
Author(s): Daniel S. Oh, David C. Adamson and John P. Kirkpatrick
Affiliation:
Keywords: Brachytherapy, charged particle therapy, glioma, radiotherapy, radiosurgery, radioimmunotherapy, biochemotherapies, Glioblastoma multiforme (GBM), radiosensitizers, CT scans
Abstract: Malignant glioma remains a disease with poor prognosis despite recent advances in the multidisciplinary care of this disease. Herein we review the evolution of and recent advances in radiation therapy for malignant glioma that have allowed for more targeted therapy, potentially improving efficacy while decreasing normal tissue toxicity. Current and emerging techniques are presented, including stereotactic radiotherapy and radiosurgery, brachytherapy, radioimmunotherapy, and charged particle therapy, as well as the combination of these modalities with novel targeted biochemotherapies.
Export Options
About this article
Cite this article as:
S. Oh Daniel, C. Adamson David and P. Kirkpatrick John, Targeted Radiotherapy for Malignant Gliomas, Current Drug Discovery Technologies 2012; 9(4) . https://dx.doi.org/10.2174/157016312803305870
DOI https://dx.doi.org/10.2174/157016312803305870 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design An Analysis of Structure-function Co-relation between GLI Oncoprotein and HLA Immune-gene Transcriptional Regulation through Molecular Docking
Current Cancer Therapy Reviews Inhibitors of Cathepsin B
Current Medicinal Chemistry A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets The Emerging Role of EMT-related lncRNAs in Therapy Resistance and their Applications as Biomarkers
Current Medicinal Chemistry Thrombospondins as Anti-Angiogenic Therapeutic Agents
Current Pharmaceutical Design Assessment In Vitro of a Novel Therapeutic Strategy for Glioma, Combining Herpes Simplex Virus HSV1716-mediated Oncolysis with Gene Transfer and Targeted Radiotherapy
Medicinal Chemistry Meet Our Associate Editorial Board Member
Current Drug Delivery Preparation, Chemical and Electrical Characterizations of Lipid Nanoparticles Loaded with Dihydroxybenzophenone
Medicinal Chemistry Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry Biochemistry and Biology of 2'-Fluoro-2'-Deoxythymidine (FT), A Putative Highly Selective Substrate for Thymidine Kinase Type 2 (TK2)
Current Radiopharmaceuticals Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment
Current Signal Transduction Therapy Discovery of Potent Natural-Product-Derived SIRT2 Inhibitors Using Structure- Based Exploration of SIRT2 Pharmacophoric Space Coupled With QSAR Analyses
Anti-Cancer Agents in Medicinal Chemistry New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight
Anti-Cancer Agents in Medicinal Chemistry A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology Yttrium-90 – Current Status, Expected Availability and Applications of a High Beta Energy Emitter
Current Radiopharmaceuticals Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery